Juno Therapeutics Inc is a US-based biopharmaceutical company. It is focused on developing cellular immunotherapies for the treatment of cancer. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. The product pipeline of the company consists of the therapeutics for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, lung cancer, mesothelioma, multiple myeloma, neuroblastoma, Non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer and triple-negative breast cancer. The company primarily derives revenue from the collaboration and license agreements.